경동제약

011040KOSDAQ의약품 제조업

51.5 / 100

Reference Date: 2026-07-24

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Slightly up 2.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongdong Pharmaceutical, established in 1976, is a company specializing in the manufacturing and sales of pharmaceuticals. Its business segments include pharmaceuticals (accounting for ~95% of sales), leasing, and others. Key products include DuoLoban tablets and Alpotin soft capsules, targeting rising demand due to aging populations and Western dietary habits. The company is expanding exports and developing new products, including OTC drugs and health supplements.

Number of Employees

363people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

15.70Industry Average 11.233.0Point

Higher than industry avg (caution)

PBR

0.67Industry Average 0.814.0Point

In line with industry avg

ROE

3.76Industry Average 4.012.5Point

Below industry avg

Debt Ratio

10.24Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲151.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 4,960Won52-week high 6,16052-week low 4,720

1-month return4.0Point

1m +2.69% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14
Neutral주식등의대량보유상황보고서(일반)2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-07-06